Emerging iPS cell colony

Stem Cells – Failings and Deliveries

September 2009. Failings of stem cell applications raise questions on deliverables. How does venture capital respond? Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, as well as interests of venture capital, and evaluates the balance. Still full of insights many years after the first publication.Reading time: 4 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section